ANI PHARMACEUTICALS, INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ANI PHARMACEUTICALS, INC (ANIP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $6.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $1.40M.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $216.00K.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.64M.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.71M.
- ANI PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.64M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $5.24M 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $216.00K derived: sum of 2 quarters · filed 2026-02-27 | $4.71M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $4.50M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $4.50M 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |